← Oncology Approval Tracker

FDA DECISION ·

Lifyorli + nab-paclitaxel

relacorilant with nab-paclitaxel · Corcept Therapeutics

FDA approvalNew therapyOvarian and related cancers
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after one to three systemic regimens, including at least one with bevacizumab.

LAMPGEN ANALYSIS

Why it matters

This adds a glucocorticoid receptor antagonist to a taxane regimen in a defined previously treated population. The prior bevacizumab requirement matters for applicability.

What research teams should watch

Capture platinum resistance timing, prior bevacizumab and concurrent glucocorticoid use. Separate label eligibility from trial exclusions.

PRIMARY RECORDS

Sources